
TALS
Healthcare · Biotechnology · $119.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 15, 2024 | Time not confirmed | -0.30 | 0.00 | +100.0% |
| Nov 8, 2023 | Before the open | -0.06 | 0.00 | +100.0% |
| Aug 14, 2023 | Before the open | -0.20 | -0.35 | -74.8% |
| May 15, 2023 | After the close | -0.35 | -0.54 | -54.3% |
| Mar 16, 2023 | Time not confirmed | -0.49 | -5.20 | -961.2% |
| Nov 10, 2022 | Before the open | -0.46 | -0.46 | 0.0% |
| Aug 15, 2022 | Before the open | -0.46 | -0.44 | +4.3% |
| May 12, 2022 | After the close | -0.35 | -0.45 | -28.6% |
| Mar 17, 2022 | After the close | -0.35 | -0.35 | 0.0% |
| Nov 12, 2021 | Before the open | -0.30 | -0.32 | -6.7% |
| Aug 12, 2021 | Before the open | -0.26 | -0.41 | -57.7% |
| May 10, 2021 | After the close | -0.26 | -1.30 | -400.0% |
| Mar 3, 2021 | Time not confirmed | — |
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc., in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune…
| -0.16 |
| — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.76 | — |